These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 3688552)
1. Serum ionized calcium--a predictor of therapeutic response to slow calcium channel blockade in essential hypertension. Midtbø K; Hals O Angiology; 1987 Nov; 38(11):841-6. PubMed ID: 3688552 [TBL] [Abstract][Full Text] [Related]
2. Can blood pressure reduction induced by slow calcium channel blockade (verapamil) be reversed by calcium infusion? Midtbø K; Hals O Pharmacol Toxicol; 1987 May; 60(5):330-2. PubMed ID: 3615342 [TBL] [Abstract][Full Text] [Related]
3. Treatment of mild to moderate hypertension with verapamil slow-release in outpatients. Collaborative Group of the Spanish League for the Fight Against Hypertension. Gómez Pajuelo C; Pérez Naranjo J; Ruiz Martínez I J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S50-2. PubMed ID: 2475687 [TBL] [Abstract][Full Text] [Related]
4. Depressor effects of ionized calcium infusion in essential hypertension. Midtbo KA; Hals O Angiology; 1987 Feb; 38(2 Pt 1):109-15. PubMed ID: 3826747 [TBL] [Abstract][Full Text] [Related]
5. The efficacy and duration of action of sustained-release verapamil in essential hypertension. McCormack PM; Latham AN; Mee F; Atkins N; O'Brien ET; O'Malley K J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S34-7. PubMed ID: 2475682 [TBL] [Abstract][Full Text] [Related]
6. Verapamil sustained-release in renal parenchymal hypertension: effect on blood pressure, kidney function, angiotensin II, aldosterone, arginine vasopressin, atrial natriuretic peptide, and lipoproteins. Eiskjaer H; Pedersen EB; Rasmussen LM; Jespersen B J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S17-22. PubMed ID: 2475677 [TBL] [Abstract][Full Text] [Related]
7. [The effects of slow-release verapamil in relation to plasma concentration in aged hypertensives. A study with continuous monitoring of arterial pressure and electrocardiogram]. Canonico V; Bonaduce D; De Caprio L; Nicolino A; Forgione L; Petretta M; Rengo F G Ital Cardiol; 1990 Oct; 20(10):924-32. PubMed ID: 2090531 [TBL] [Abstract][Full Text] [Related]
8. Serum concentration and antihypertensive effect of slow-release verapamil. Schütz E; Ha HR; Bühler FR; Follath F J Cardiovasc Pharmacol; 1982; 4 Suppl 3():S346-9. PubMed ID: 6184566 [TBL] [Abstract][Full Text] [Related]
9. Sustained-release verapamil as a first-step drug in the treatment of mild to moderate hypertension. Karcier SM; Orbay B; Ozder AB; Gürses N; Aytekin S; Satar S; Oztürk M; Demiroğlu C J Int Med Res; 1989; 17(3):268-76. PubMed ID: 2767329 [TBL] [Abstract][Full Text] [Related]
10. A new sustained-release formulation of verapamil in the treatment of hypertension. Midtbo KA; Hals O; Lauve O J Clin Hypertens; 1986 Sep; 2(3 Suppl):125S-132S. PubMed ID: 3540222 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of enalapril and sustained-release verapamil in older patients with mild to moderate essential hypertension. Weir MR; Cassidy CA; Hall PS; Lancaster A; Schubert C; Urick A; Saunders E; Kong BW; Jenkins P; Lavin PT Clin Ther; 1990; 12(2):139-48. PubMed ID: 2354483 [TBL] [Abstract][Full Text] [Related]
12. Effect of sustained-release verapamil therapy on the blood pressure at rest and on the pressor response to isometric exertion in hypertensive patients. Cardillo C; Musumeci V; Savi L; Guardigli R; Mores N; Folli G Eur J Clin Pharmacol; 1988; 34(6):549-53. PubMed ID: 3169108 [TBL] [Abstract][Full Text] [Related]
13. The effects of slow-release verapamil on blood pressure and cardiovascular system in essential hypertension. Meric M; Adalet K; Erzengin F; Korkut F; Okur O; Büyüköztürk K J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S42-4. PubMed ID: 2475684 [TBL] [Abstract][Full Text] [Related]
14. Long-term safety and efficacy comparison of immediate-release and sustained-release oral verapamil in systemic hypertension. Frishman WH; Eisen G; Charlap S; Strom JA J Clin Hypertens; 1987 Dec; 3(4):605-9. PubMed ID: 3134517 [TBL] [Abstract][Full Text] [Related]
15. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. Pepine CJ; Handberg EM; Cooper-DeHoff RM; Marks RG; Kowey P; Messerli FH; Mancia G; Cangiano JL; Garcia-Barreto D; Keltai M; Erdine S; Bristol HA; Kolb HR; Bakris GL; Cohen JD; Parmley WW; JAMA; 2003 Dec; 290(21):2805-16. PubMed ID: 14657064 [TBL] [Abstract][Full Text] [Related]
16. [The TEAM study--a study of the effectiveness and tolerance of treatment of essential hypertension with a fixed combination of trandolapril and verapamil]. Widimský J; Dzúrik R Vnitr Lek; 1998 Jun; 44(6):326-31. PubMed ID: 9820054 [TBL] [Abstract][Full Text] [Related]
17. Instant and sustained-release verapamil in the treatment of essential hypertension. Midtbø K; Hals O; van der Meer J; Storstein L; Lauve O Am J Cardiol; 1986 Feb; 57(7):59D-63D. PubMed ID: 3513516 [TBL] [Abstract][Full Text] [Related]
18. Effects of slow-release verapamil and nitrendipine on office and 24-hour ambulatory blood pressure in hypertensive patients. Pannarale G; Puddu PE; Campbell SV; Collauto F; Stazi F; Reale A J Cardiovasc Pharmacol; 1992; 19 Suppl 2():S53-6. PubMed ID: 1377307 [TBL] [Abstract][Full Text] [Related]
19. Hydrochlorothiazide is not additive to verapamil in treating essential hypertension. Nicholson JP; Resnick LM; Laragh JH Arch Intern Med; 1989 Jan; 149(1):125-8. PubMed ID: 2643413 [TBL] [Abstract][Full Text] [Related]